BCS: Radiological Tests Little Use in Detecting Breast Mets For human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, a subcutaneous formulation of trastuzumab is non-inferior ...
Trastuzumab is often used as an adjuvant therapy in early-stage and metastatic HER2-positive breast cancer. A new study found that use of biosimilars increased from 18.3% of intravenous (IV) ...
Oncology biologics are one of the fastest-growing segments of pharmaceutical development, bringing more options to patients, including those with human epidermal growth factor receptor 2 ...
In Europe, the Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions on a new formulation of trastuzumab (Herceptin, Roche), and for product label extensions for lapatinib ...
Enhanced anti-tumor effect of trastuzumab combined with less cardiotoxic anthracycline, amrubicin, in a HER2-positive human cancer xenograft in athymic mice No significant financial relationships to ...
The median total clinic time was not significantly shorter for patients who received subcutaneous trastuzumab/pertuzumab than for those who received the intravenous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results